ESMO 2023 | SANO-trial: neoadjuvant chemo-RT followed by surgery vs. active surveillance for oesophageal cancer

Berend J. Van der Wilk, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, discusses a noninferiority trial evaluating active surveillance versus standard surgery in patients with clinically complete response (CCR) after neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer. The study included 198 patients in active surveillance and 111 in standard surgery. Active surveillance, with surgery performed only upon locoregional regrowth detection, demonstrated noninferior overall survival (OS) compared to standard surgery. During active surveillance, 35% maintained CCR, 48% developed locoregional regrowths, and 17% developed distant metastases. Active surveillance also showed improved short-term health-related quality of life (HRQOL). This interview occurred at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.